Text Size

A Study of Mometasone Furoate Nasal Spray in Perennial Allergic Rhinitis (Study P03748)(COMPLETED)

This study has been completed.
Sponsor:
Information provided by:
Schering-Plough
ClinicalTrials.gov Identifier:
NCT00779545
First received: October 23, 2008
Last updated: NA
Last verified: October 2008
History: No changes posted
  Purpose

This is a multicenter, randomized, double-blind within the dose level, parallel group comparison of mometasone furoate nasal spray in subjects with perennial allergic rhinitis to examine the minimal effective dose, the recommended dose, and the dosing regimen.


Condition Intervention Phase
Rhinitis, Allergic, Perennial
 Drug: Placebo
Drug: Mometasone furoate
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Dose Finding and Dose Regimen Study of Mometasone Furoate Nasal Spray in Perennial Allergic Rhinitis

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Schering-Plough:

Primary Outcome Measures:
  • Change in 4 nasal symptom score (sneezing attack, rhinorrhea, nasal congestion, and nasal itching) from baseline at Week 2 [ Time Frame: After 2 weeks of treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in each nasal symptom (sneezing attack, rhinorrhea, nasal congestion, and nasal itching) [ Time Frame: After 1 and 2 weeks of treatment ] [ Designated as safety issue: No ]
  • Overall improvement [ Time Frame: After 1 and 2 weeks of treatment ] [ Designated as safety issue: No ]
  • QOL score [ Time Frame: At initial day of treatment and after 2 weeks of treatment ] [ Designated as safety issue: No ]
  • Adverse events [ Time Frame: From initial day of treatment until 7-10 days after treatment is stopped. ] [ Designated as safety issue: Yes ]
  • Laboratory tests [ Time Frame: From initial day of treatment until treatment is stopped. ] [ Designated as safety issue: Yes ]

Enrollment: 455
Study Start Date: April 2004
Study Completion Date: September 2004
Primary Completion Date: September 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
The placebo group was divided into 3 groups receiving 1, 2 or 4 sprays/nostril. The regimen of each placebo group was BID
 Drug: Placebo
One, two, or four sprays of placebo are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks.
Other Name: Placebo
Experimental: Mometasone furoate nasal spray 100 mcg QD Drug: Placebo
One, two, or four sprays of placebo are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks.
Other Name: Placebo
Drug: Mometasone furoate
One spray of mometasone furoate 50 mcg is administered to the left and right nostrils in the morning, and one spray of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 100 mcg.
Other Names:
  • Nasonex
  • SCH 32088
Experimental: Mometasone furoate nasal spray 200 mcg QD Drug: Placebo
One, two, or four sprays of placebo are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks.
Other Name: Placebo
Drug: Mometasone furoate
Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and two sprays of placebo to the left and right at night for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
Other Names:
  • Nasonex
  • SCH 32088
Experimental: Mometasone furoate nasal spray 400 mcg QD Drug: Placebo
One, two, or four sprays of placebo are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks.
Other Name: Placebo
Drug: Mometasone furoate
Four sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and four sprays of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
Other Names:
  • Nasonex
  • SCH 32088
Experimental: Mometasone furoate nasal spray 100 mcg BID Drug: Mometasone furoate
One spray of mometasone furoate 50 mcg is administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
Other Names:
  • Nasonex
  • SCH 32088
Experimental: Mometasone furoate nasal spray 200 mcg BID Drug: Mometasone furoate
Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
Other Names:
  • Nasonex
  • SCH 32088

  Eligibility

Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients of mongoloid race residing in Japan who satisfy all of the following criteria:

    • Patients having symptoms of allergic rhinitis of moderate or severe degree, according to the classification of severity in the guidelines for the treatment of nasal allergy (partial revision) as well as a score of at least 4 in the score of 4 nasal symptoms, at the time of obtaining the informed consent during the pretreatment observation period.
    • Patients in whom the skin or specific IgE test is positive and the cytological examination for eosinophils in nasal discharge or nasal challenge test is positive.
    • Out-patients aged 16 years or over at the time of obtaining the informed consent.
    • Male or female.
    • Patients from whom the informed consent can be obtained in writing (or the informed consent can be obtained from the patient's legally acceptable representative, if under 20 years).
    • Patients who can daily complete the nasal allergy diary.

Exclusion Criteria:

  • Patients who meet any of the following exclusion criteria are not included in the present study:

    • Patients with a complication of tuberculous disease or lower respiratory tract infection, or patients with a complication of acute upper respiratory tract inflammation or acute laryngopharyngitis which the (sub) investigator considers necessary to treat at the time of enrollment in the treatment.
    • Patients with a complication of infection or systemic mycosis for which no effective antibiotics are available.
    • Patients with unhealed nasal septum ulcer, nasal surgery, or nasal trauma.
    • Patients with hypersensitivity to steroids and mometasone furoate.
    • Patients who are pregnant, nursing, or possibly pregnant, or who desire to become pregnant during the study period.
    • Patients with severe hepatic, renal, or cardiac disorder, blood disease, diabetes, hypertension, or other serious complication, suffering from problems with systemic condition.
    • Patients in whom pollen is an overlapping allergen and the study is planned to be implemented in the pollen release season.
    • Patients with a complication of vasomotor rhinitis or eosinophilic rhinitis.
    • Patients with a complication of nose disease which may interfere with efficacy evaluation of the investigational product.
    • Patients who were complicated by acute upper respiratory tract inflammation during the 7-day observation period prior to enrollment which may affect the nasal symptoms.
    • Patients who have previously received mometasone furoate nasal spray.
    • Patients who have participated in clinical trial of other investigational product(s) within 4 months before obtaining the informed consent or are participating at present.
    • Patients in whom prior medication effective against allergic rhinitis was withdrawn not long enough before initiation of treatment with the investigational product or the preceding medication cannot be withdrawn.
    • Patients who are being treated with specific desensitization therapy or nonspecific allassotherapy or in whom such the therapy was withdrawn within 3 months before obtaining the informed consent (except for patients receiving the maintenance therapy at present in whom the therapy began more than 6 months before obtaining the informed consent).
    • Other patients whom the (sub) investigator judged to be inappropriate for participation in the present study.
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Head, Clinical Trials Registry & Results Disclosure Group, Schering-Plough
ClinicalTrials.gov Identifier: NCT00779545     History of Changes
Other Study ID Numbers: P03748, JPC-03-342-20
Study First Received: October 23, 2008
Last Updated: October 23, 2008
Health Authority: Japan: Pharmaceuticals and Medical Devices Agency

Additional relevant MeSH terms:
Rhinitis
Rhinitis, Allergic, Perennial
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
 Hypersensitivity
Immune System Diseases
Mometasone furoate
Anti-Allergic Agents
Therapeutic Uses
Pharmacologic Actions
Anti-Inflammatory Agents

ClinicalTrials.gov processed this record on June 18, 2013